
|Articles|October 24, 2012
VIDEO: Robert Frantz, MD, FACC, Discusses Costs Associated With Pulmonary Arterial Hypertension
Robert Frantz, MD, FACC, Director, Pulmonary Hypertension Clinic, Mayo Clinic, says that the issue of cost is an important factor in treating patients with pulmonary arterial hypertension.
Advertisement
Robert Frantz, MD, FACC, Director, Pulmonary Hypertension Clinic, Mayo Clinic, says that the issue of cost is an important factor in treating patients with pulmonary arterial hypertension. Dr Frantz also says that patients with pulmonary arterial hypertension who contract a blood stream infection will most likely require costly hospitalization and run the risk of other health issues.
This video was taken on Sunday, October 21 at the CHEST 2012 conference in Atlanta, GA.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
MFN Drug Agreements Could Raise Prices Worldwide
2
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
3
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
4
FDA Clears First Alzheimer Blood Test for Adults as Young as 40
5




